Overcoming the challenges associated with identification of deep intronic variants by whole genome sequencing
Clinical Genetics · 2023-06 · 103 (6) · 693-698
DOI: 10.1111/cge.14305 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Genetics, online erschienen am 06.02.2023. Verfasst von Marie Dirix und 8 weiteren Autor:innen. Beteiligte Einrichtung: INSERM U1163, Laboratoire des Maladies Rénales Héréditaires, Institut Imagine, Université Paris-Cité, France. Hauptthemen laut MEDLINE: Nephrotic Syndrome. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fondation pour la Recherche Médicale, Agence Nationale de la Recherche.
Abstract (Originalsprache)
Whole‐genome sequencing (WGS) now allows identification of multiple variants in non‐coding regions. The large number of variants identified by WGS however complicates their interpretation. Through identification of the first deep intronic variant in NPHS2 , which encodes podocin, a protein implicated in autosomal recessive steroid resistant nephrotic syndrome (SRNS), we compare herein three different tools including a newly developed targeted NGS‐based RNA‐sequencing to explore the splicing effect of intronic variations. WGS identified two different variants in NPHS2 eventually involved in the disease. Through RT‐PCR, exon‐trapping Minigene assay and targeted RNA sequencing, we were able to identify the splicing defect in NPHS2 mRNA from patient kidney tissue. Only targeted RNA‐seq simultaneously analyzed the effect of multiple variants and offered the opportunity to quantify consequences on splicing. Identifying deep intronic variants and their role in disease is of utmost importance. Alternative splicing can be predicted by in silico tools but always requires confirmation through functional testing with RNA analysis from the implicated tissue remaining the gold standard. When several variants with potential effects on splicing are identified by WGS, a targeted RNA sequencing panel could be of great value.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- INSERM U1163, Laboratoire des Maladies Rénales Héréditaires, Institut Imagine, Université Paris-Cité, France.
- Laboratoires de biologie médicale SeqOIA, Paris, France.
- Centre de Référence des Maladies Rénales Héréditaires de l'Enfant et de l'Adulte MARHEA, Hôpital Necker-Enfants Malades, Paris, France.
- Service de Médecine Génomique des Maladies Rares, APHP, Université Paris-Cité, France.
ORCID-Profile: Laurence Heidet
Förderung
- Fondation pour la Recherche Médicale
- Agence Nationale de la Recherche
Zitieren
APA
Dirix, M., Gribouval, O., Arrondel, C., Benjelloun, S., Boyer, O., Charbit, M., Antignac, C., Heidet, L., & Dorval, G. (2023). Overcoming the challenges associated with identification of deep intronic variants by whole genome sequencing. Clinical Genetics, 103(6), 693-698. https://doi.org/10.1111/cge.14305
Vancouver
Dirix M, Gribouval O, Arrondel C, Benjelloun S, Boyer O, Charbit M, et al. Overcoming the challenges associated with identification of deep intronic variants by whole genome sequencing. Clinical Genetics. 2023;103(6):693-698. doi:10.1111/cge.14305
BibTeX
@article{Dirix2023,
author = {Dirix, Marie and Gribouval, Olivier and Arrondel, Christelle and Benjelloun, Saadia and Boyer, Olivia and Charbit, Marina and Antignac, Corinne and Heidet, Laurence and Dorval, Guillaume},
title = {Overcoming the challenges associated with identification of deep intronic variants by whole genome sequencing},
journal = {Clinical Genetics},
year = {2023},
volume = {103},
number = {6},
pages = {693--698},
doi = {10.1111/cge.14305}
}
EUVIMED